Axovant discontinues dementia candidate

Axovant Sciences Ltd. (NASDAQ:AXON) discontinued development of intepirdine (RVT-101) after the candidate missed the primary endpoint in both the Phase IIb HEADWAY and Phase II Gait and Balance trials to

Read the full 302 word article

User Sign In